CSL Limited

CSL Limited is one of the world’s leading biotechnology companies specializing in plasma-derived therapies, vaccines, recombinant proteins, gene therapies, and innovative medicines for patients with rare and serious diseases. Founded in 1916 as the Commonwealth Serum Laboratories, the company is headquartered in Melbourne, Victoria, Australia. Over more than a century, CSL has evolved into a global biopharmaceutical leader with operations spanning over 40 countries and products distributed to more than 100 markets worldwide.

The company operates through key business divisions including CSL Behring, CSL Seqirus, and CSL Vifor. CSL Behring develops therapies for immunology, hematology, respiratory diseases, and rare genetic disorders. CSL Seqirus is among the world’s largest influenza vaccine manufacturers, while CSL Vifor focuses on iron deficiency, nephrology, and cardio-renal therapies. The company’s research strategy emphasizes biologics, plasma science, recombinant technologies, and advanced biotechnology platforms to address unmet medical needs.

CSL invests significantly in research and development, global manufacturing infrastructure, and plasma collection networks to ensure high-quality products and supply reliability. With strong commitments to sustainability, patient safety, regulatory excellence, and scientific innovation, CSL continues to improve healthcare outcomes through life-saving therapies. Its long history of biotechnology leadership and global partnerships has established CSL as one of the most respected names in the international biopharmaceutical industry.